Monitor the next quarterly filing for any strategic or financial shifts under the new CFO. The appointment of a CFO with capital markets and M&A experience could signal preparation for financing or partnership activity, but no immediate catalyst is indicated.
Price Chart
Executive Summary
SCYNEXIS announced the retirement of CFO Ivor Macleod effective September 9, 2026, and the immediate appointment of Sanjay Subramanian as new CFO. The transition is orderly with a one-month overlap, and Mr. Subramanian brings relevant biopharma finance experience including a prior acquisition exit. This is a routine executive change with no new financial disclosures or strategic updates.
Key Facts
- CFO Ivor Macleod retired effective September 9, 2026 and will remain through October 9, 2026 for transition support.
- Sanjay Subramanian appointed CFO effective September 9, 2026; he previously served as CFO at Inozyme Pharma and Ocugen.
- New CFO receives a $500,000 base salary, $20,000 sign-on bonus, up to 40% annual bonus, and a stock option for 100,000 shares at $4.91 (closing price on grant date) vesting over four years.
- Severance provides 9 months base salary (18 months if terminated within 12 months after a change of control) plus accelerated equity vesting.
Financial Impact
No material financial impact from the executive change. New CFO compensation is within normal range for a clinical-stage biotech of this market cap.
Risk Factors
- No immediate risks identified from this routine executive transition.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001178253-26-000031 |
| Document: scyx-ex99_1.htm | 0001178253-26-000031 |
| Document: 0001178253-26-000031-index-headers.html | 0001178253-26-000031 |
| Document: 0001178253-26-000031-index.html | 0001178253-26-000031 |
| Document: 0001178253-26-000031.txt | 0001178253-26-000031 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 10, 2026 22d ago | 8-K | $4.70 $4.45 | ▼ −5.32% | ▼ −4.82% | $5.12 (+8.94%) |
Jun 26, 2026 14w ago | 8-K | $3.87 $4.73 | ▲ +22.22% | ▲ +20.83% | $5.12 (+32.30%) |
May 22, 2026 19w ago | 8-K | $5.45 $5.33 | ▼ −2.17% | ▼ −3.25% | $5.12 (−6.02%) |
May 11, 2026 20w ago | Press Release | $6.24 $5.26 | ▲ +15.77% | ▲ +15.17% | $5.12 (+17.95%) |
Apr 20, 2026 23w ago | 8-K | $8.48 $7.89 | ▼ −6.98% | ▼ −8.06% | $5.12 (−39.62%) |
Mar 31, 2026 26w ago | Press Release | $7.34 $7.97 | ▲ +8.62% | ▲ +4.67% | $5.12 (−30.21%) |
Mar 4, 2026 30w ago | Press Release | $6.34 $7.12 | ▲ +12.34% | ▲ +14.58% | $5.12 (−19.24%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access